BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  US Device


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Cubist Pharmaceuticals, Inc. 

65 Hayden Avenue

Lexington  Massachusetts  02421  U.S.A.
Phone: 781-860-8660 Fax: 781-861-0566


View Clinical Trials from BioPharm Insight

There’s something special about working at Cubist Pharmaceuticals.

We provide a progressive, flexible work environment and a highly competitive total rewards program designed to meet your work/life needs now and in the future. In our product, our pipeline and in our supportive culture, Cubist demonstrates its continuing commitment of excellence to our employees and our shareholders.

Cubist is a bio-pharmaceutical company focused on the research, commercial¬ization and creation of pharmaceutical products that address unmet medical needs in the acute care environment. CUBICIN® , (daptomycin for injection), our marketed product, has been used in the treatment of more than an estimated 1.1 million patients with serious and sometimes life-threatening infections. CUBICIN has generated hundreds of millions of dollars in annual sales that helped propel Cubist into one of the Commonwealth's best-performing firms as evidenced by recent recognition. Cubist was ranked among Top Pharmas on the Scrip 100 List, while Forbes recently listed Cubist as one of 14 "Productivity Powerhouses." Cubist appeared in The Boston Globe's 2010 annual list of the "Top Places to Work" in Massachusetts (for the third consecutive year).

Mass High Tech announced that Cubist ranked 13th among the top 30 Fastest-Growing Public Technology Companies in New England for 2010 and was one of only ten pharmaceutical companies to make that list. Cubist also debuted as the 31st overall company and top pharmaceutical company named to FORTUNE's 2010 List of 100 Fastest-Growing Companies, and was named to the 2010 Deloitte Technology Fast 500™ for the sixth consecutive year.

 Key Statistics

Ownership: Public

Web Site: Cubist Pharmaceuticals, Inc.
Employees: ~600
Symbol: CBST

 Company News
Cubist Pharmaceuticals, Inc. (CBST) Issues Voluntary Nationwide Recall Of One Lot Of CUBICIN (Daptomycin For Injection) 500 Mg In 10 Ml Single Use Vials Due To Presence Of Particulate Matter 4/18/2014 10:23:04 AM    More...
Cubist Pharmaceuticals, Inc. (CBST) To Announce First Quarter 2014 Financial Results On Tuesday, April 22, 2014 4/15/2014 6:42:23 AM    More...
FDA Advisory Committee Unanimously Recommends Approval Of FDA’s SIVEXTRO™ (Tedizolid Phosphate) As Treatment For Serious Skin Infections 4/1/2014 8:18:49 AM    More...
Cubist Pharmaceuticals, Inc. (CBST) Appoints Robert J. Perez To Board Of Directors 4/1/2014 7:14:50 AM    More...
Cubist Pharmaceuticals, Inc. (CBST) Announces European Medicines Agency Acceptance Of Tedizolid Marketing Authorization Application For Review 2/27/2014 9:12:37 AM    More...
Cubist Pharmaceuticals, Inc. (CBST) & Cambridge Science Festival Launch "Germ Challenge" Science Contest 2/13/2014 8:26:22 AM    More...
Cubist Pharmaceuticals, Inc. (CBST) To Present At February Investor Conferences 2/10/2014 9:50:38 AM    More...
Cubist Pharmaceuticals, Inc. (CBST) Reports Fourth Quarter And Full Year 2013 Financial Results; Provides 2014 Revenue Guidance 1/24/2014 6:49:13 AM    More...
Cubist Pharmaceuticals, Inc. (CBST) Announces Fourth Quarter/Full-Year 2013 Revenues; Provides Pipeline Update 1/13/2014 7:09:44 AM    More...
Cubist Pharmaceuticals, Inc. (CBST) Submits Clinical Trial Application To Initiate First-In-Human Study Of CB-618—A Beta-Lactamase Inhibitor Discovered To Combat Antibiotic Resistance 1/10/2014 9:52:03 AM    More...